# Newpath Management

> Newpath Management is a VC fund in Boston backing Biotechnology and Medical. See 26 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 26
- Last investment: May 2026
- Lead investor: 50%
- Fund size: $350M
- Last fund: Dec 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/newpath-partners
- Website: http://www.newpath.partners

Newpath Management is a VC fund in Boston focused on Biotechnology and Medical. Newpath Partners, LP is a life science venture firm dedicated to excellent science and to forming partnerships based on trust and a shared vision.

## Contacts

5 contacts available for Newpath Management. Shizune tracks 3 team members at Newpath Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/newpath-management-l-p?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 11 | 42% |
| Medical | 8 | 31% |
| Health Care | 6 | 23% |
| Life Science | 3 | 12% |
| Therapeutics | 3 | 12% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 9 | 35% |
| Series B | 6 | 23% |
| Seed | 2 | 8% |
| Funding Round | 2 | 8% |
| Series C | 1 | 4% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Thomas Cahill | Founder and Managing Partner | 10 | https://shizune.co/investors/profile/thomas-cahill-bea1 |
| Daniel Yadegar | CMO & Co-Founder | 2 | https://shizune.co/investors/profile/daniel-yadegar |
| Greg McGraw | Controller | 0 | https://shizune.co/investors/profile/greg-mcgraw-2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CREATE Medicines | Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners. | $122M | Series B | May 14, 2026 |  |
| CREATE Medicines | Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners. | $122M | Series B | May 14, 2026 |  |
| Leal Therapeutics | Leal Therapeutics develops novel therapeutics for patients. | $30M | Series A | Aug 27, 2025 |  |
| nChroma Bio | nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques. | $75M | Venture - Series Unknown | Dec 11, 2024 |  |
| Metsera | Metsera operates as a clinical-stage biopharmaceutical company. | $215M | Series B | Nov 13, 2024 |  |
| Leal Therapeutics | Leal Therapeutics develops novel therapeutics for patients. |  | Debt Financing | Oct 30, 2024 |  |
| Leal Therapeutics | Leal Therapeutics develops novel therapeutics for patients. | $6M | Venture - Series Unknown | Oct 30, 2024 |  |
| Autobahn Therapeutics | Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The company’spipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego. | $100M | Series C | Jul 24, 2024 |  |
| Autobahn Therapeutics | Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The company’spipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego. | $100M | Series C | Jul 24, 2024 |  |
| Metsera | Metsera operates as a clinical-stage biopharmaceutical company. | $290M | Series A | Apr 18, 2024 |  |

10 of 26 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 18 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 11 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 8 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 7 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 5 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 5 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Newpath Management invest in?

Newpath Management invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Newpath Management?

Public channels for Newpath Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Newpath Management?

The team at Newpath Management includes Thomas Cahill (Founder and Managing Partner), Daniel Yadegar (CMO & Co-Founder) and Greg McGraw (Controller). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co